ERα-Dependent E2F Transcription Can Mediate Resistance to Estrogen Deprivation in Human Breast Cancer
- 1 September 2011
- journal article
- Published by American Association for Cancer Research (AACR) in Cancer Discovery
- Vol. 1 (4), 338-351
- https://doi.org/10.1158/2159-8290.cd-11-0101
Abstract
Most estrogen receptor α (ER)-positive breast cancers initially respond to antiestrogens, but many eventually become estrogen-independent and recur. We identified an estrogen-independent role for ER and the CDK4/Rb/E2F transcriptional axis in the hormone-independent growth of breast cancer cells. ER downregulation with fulvestrant or small interfering RNA (siRNA) inhibited estrogen-independent growth. Chromatin immunoprecipitation identified ER genomic binding activity in estrogen-deprived cells and primary breast tumors treated with aromatase inhibitors. Gene expression profiling revealed an estrogen-independent, ER/E2F-directed transcriptional program. An E2F activation gene signature correlated with a lesser response to aromatase inhibitors in patients' tumors. siRNA screening showed that CDK4, an activator of E2F, is required for estrogen-independent cell growth. Long-term estrogen-deprived cells hyperactivate phosphatidylinositol 3-kinase (PI3K) independently of ER/E2F. Fulvestrant combined with the pan-PI3K inhibitor BKM120 induced regression of ER+ xenografts. These data support further development of ER downregulators and CDK4 inhibitors, and their combination with PI3K inhibitors for treatment of antiestrogen-resistant breast cancers. Significance: ERα retains genomic activity and drives a CDK4/E2F-dependent transcriptional program despite estrogen deprivation therapy. Combined inhibition of ER and PI3K induced regression of ER+ xenografts, supporting further development of strong ER downregulators and CDK4 inhibitors, and their combination with PI3K inhibitors for the treatment of antiestrogen-resistant breast cancers. Cancer Discovery; 1(4); 338–51. ©2011 AACR. Read the Commentary on this article by Van Tine et al., p. 287 This article is highlighted in the In This Issue feature, p. 275Keywords
Other Versions
This publication has 55 references indexed in Scilit:
- FOXA1 is a key determinant of estrogen receptor function and endocrine responseNature Genetics, 2010
- An oestrogen-receptor-α-bound human chromatin interactomeNature, 2009
- Biological determinants of endocrine resistance in breast cancerNature Reviews Cancer, 2009
- Androgen Receptor Regulates a Distinct Transcription Program in Androgen-Independent Prostate CancerCell, 2009
- Genomic Antagonism between Retinoic Acid and Estrogen Signaling in Breast CancerCell, 2009
- Tailoring to RB: tumour suppressor status and therapeutic responseNature Reviews Cancer, 2008
- Coordinate regulation of Fanconi anemia gene expression occurs through the Rb/E2F pathwayOncogene, 2008
- Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trialThe Lancet Oncology, 2008
- Mechanisms of primary and secondary estrogen target gene regulation in breast cancer cellsNucleic Acids Research, 2007
- Genome-wide analysis of estrogen receptor binding sitesNature Genetics, 2006